Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the ex­ecs at Neo­gene had some lofty goals in mind when they de­cid­ed to try their hand at a cell ther­a­py that could tack­le sol­id tu­mors.

Its founders have helped hone a new ap­proach that would pack in mul­ti­ple neoanti­gen tar­gets to cre­ate a per­son­al­ized TCR treat­ment that would not just make the leap from blood to sol­id tu­mors, but do it with dura­bil­i­ty. And they man­aged to make their way rapid­ly to the clin­ic, un­veil­ing their first Phase I pro­gram for ad­vanced tu­mors just last May.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.